Exceptional product

Miraculins currently has five cancer diagnostic programs under development designed to assist with the early detection of cancer, thereby reducing suffering, saving lives and cutting healthcare costs.

Prostate cancer diagnostic

Miraculins' prostate cancer diagnostic is currently under development. It is a simple urine-based test that can be used to test men with an unclear diagnosis based on PSA levels. The test is able to correctly identify cancer positives, while correctly classifying those without cancer with a sensitivity and specificity greater than the PSA test.

Colorectal cancer diagnostic

Miraculins' colorectal cancer diagnostic is currently under development. It is a simple blood test designed to detect colorectal cancer in the early stages that can be used to correctly identify cancer positives, while correctly classifying those without cancer with a sensitivity and specificity greater than the fecal occult blood test, the current standard for initial colorectal screening.

Pancreatic cancer diagnostic

Miraculins' pancreatic cancer diagnostic is currently under development. It is a simple blood test designed to detect pancreatic cancer in the early stages. It can be used to correctly identify pancreatic cancer positives, while correctly classifying those with pancreatitis, a rare disease in which the pancreas becomes inflamed, with a high degree of sensitivity and specificity.

Gastric cancer diagnostic

Miraculins' gastric cancer diagnostic is currently under development. It is a simple blood test designed to detect gastric cancer in the early stages. It can be used to correctly identify gastric cancer positives, while correctly classifying those with benign gastric disease (non-malignant maladies such as gastritis, peptic ulcers and gastric reflux that present with similar symptoms) with a high degree of sensitivity and specificity.

Breast cancer diagnostic

Miraculins' breast cancer diagnostic is currently under development. It is a simple blood test designed to detect breast cancer in the early stages. It can be used to correctly identify breast cancer positives, while correctly classifying those without cancer with a high degree of sensitivity and specificity.